(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 April 2022 (28.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/087610 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61K 47/18* (2017.01)
A61K 9/08 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/US2021/071958

(22) International Filing Date:
21 October 2021 (21.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/104,436 22 October 2020 (22.10.2020) US

(71) Applicant: **ALLAKOS INC.** [US/US]; 825 Industrial Road, Suite 500, San Carlos, California 94070 (US).

(72) Inventors: **YOUEL, Dan**; c/o Allakos Inc., 825 Industrial Road, Suite 500, San Carlos, California 94070 (US). **CASARENO, Ruby**; c/o Allakos Inc., 825 Industrial Road, Suite 500, San Carlos, California 94070 (US).

(74) Agent: **ONUFRYK, Christina** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

(54) **Title:** ANTI-SIGLEC-8 ANTIBODY FORMULATIONS

			Median Blood Eosinophils 10^3/mL						
Route	Dose Cohort (mg/kg)	n	Baseline	1 hr	3 hr	Day 15	Day 35	Day 56	Day 85
	PBO	10	100	100	200	200	100	200	100
SC	0.3	6	110	200	20	0	0	50	100
	1.0	6	150	0	0	0	0	0	50
	3.0	6	150	0	0	0	0	0	0
	5.0	6	100	0	0	0	0	0	0
	300 mg	6	100	0	0	0	0	0	0
IV	1.0	6	100	0	0	0	0	0	0
	3.0	12	100	0	0	0	0	0	0

FIG. 9

(57) **Abstract:** The present disclosure provides pharmaceutical compositions (e.g., liquid formulations) comprising a monoclonal antibody that binds to a human Siglec-8 for subcutaneous administration, as well as articles of manufacture related thereto.

WO 2022/087610 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*